Lauren A E Erland1, Praveen K Saxena1. 1. Gosling Research Institute for Plant Preservation, Department of Plant Agriculture, University of Guelph, Guelph, Ontario, Canada.
Abstract
STUDY OBJECTIVES: Melatonin is an important neurohormone, which mediates circadian rhythms and the sleep cycle. As such, it is a popular and readily available supplement for the treatment and prevention of sleep-related disorders including insomnia and jet lag. This study quantified melatonin in 30 commercial supplements, comprising different brands and forms and screened supplements for the presence of serotonin. METHODS: A total of 31 supplements were analyzed by ultraperformance liquid chromatography with electrochemical detection for quantification of melatonin and serotonin. Presence of serotonin was confirmed through analysis by ultraperformance liquid chromatography with mass spectrometry detection. RESULTS: Melatonin content was found to range from -83% to +478% of the labelled content. Additionally, lot-to-lot variable within a particular product varied by as much as 465%. This variability did not appear to be correlated with manufacturer or product type. Furthermore, serotonin (5-hydroxytryptamine), a related indoleamine and controlled substance used in the treatment of several neurological disorders, was identified in eight of the supplements at levels of 1 to 75 μg. CONCLUSIONS: Melatonin content did not meet label within a 10% margin of the label claim in more than 71% of supplements and an additional 26% were found to contain serotonin. It is important that clinicians and patients have confidence in the quality of supplements used in the treatment of sleep disorders. To address this, manufacturers require increased controls to ensure melatonin supplements meet both their label claim, and also are free from contaminants, such as serotonin. COMMENTARY: A commentary on this article appears in this issue on page 163.
STUDY OBJECTIVES:Melatonin is an important neurohormone, which mediates circadian rhythms and the sleep cycle. As such, it is a popular and readily available supplement for the treatment and prevention of sleep-related disorders including insomnia and jet lag. This study quantified melatonin in 30 commercial supplements, comprising different brands and forms and screened supplements for the presence of serotonin. METHODS: A total of 31 supplements were analyzed by ultraperformance liquid chromatography with electrochemical detection for quantification of melatonin and serotonin. Presence of serotonin was confirmed through analysis by ultraperformance liquid chromatography with mass spectrometry detection. RESULTS:Melatonin content was found to range from -83% to +478% of the labelled content. Additionally, lot-to-lot variable within a particular product varied by as much as 465%. This variability did not appear to be correlated with manufacturer or product type. Furthermore, serotonin (5-hydroxytryptamine), a related indoleamine and controlled substance used in the treatment of several neurological disorders, was identified in eight of the supplements at levels of 1 to 75 μg. CONCLUSIONS:Melatonin content did not meet label within a 10% margin of the label claim in more than 71% of supplements and an additional 26% were found to contain serotonin. It is important that clinicians and patients have confidence in the quality of supplements used in the treatment of sleep disorders. To address this, manufacturers require increased controls to ensure melatonin supplements meet both their label claim, and also are free from contaminants, such as serotonin. COMMENTARY: A commentary on this article appears in this issue on page 163.
Authors: Josephine Arendt; Eus J W Van Someren; Richard Appleton; Debra J Skene; Torbjorn Akerstedt Journal: Clin Med (Lond) Date: 2008-08 Impact factor: 2.659
Authors: Frank A J L Scheer; Christopher J Morris; Joanna I Garcia; Carolina Smales; Erin E Kelly; Jenny Marks; Atul Malhotra; Steven A Shea Journal: Sleep Date: 2012-10-01 Impact factor: 5.849
Authors: Deepa S Maharaj; Shailendra Anoopkumar-Dukie; Beverley D Glass; Edith M Antunes; Barbara Lack; Roderick B Walker; Santy Daya Journal: J Pineal Res Date: 2002-05 Impact factor: 13.007
Authors: Michael B Wasdell; James E Jan; Melissa M Bomben; Roger D Freeman; Wop J Rietveld; Joseph Tai; Donald Hamilton; Margaret D Weiss Journal: J Pineal Res Date: 2008-01 Impact factor: 13.007
Authors: Nina Buscemi; Ben Vandermeer; Nicola Hooton; Rena Pandya; Lisa Tjosvold; Lisa Hartling; Sunita Vohra; Terry P Klassen; Glen Baker Journal: BMJ Date: 2006-02-10
Authors: Margaret M Lubas; Belinda N Mandrell; William L Greene; Carrie R Howell; Robbin Christensen; Cara I Kimberg; Chenghong Li; Kirsten K Ness; Deo Kumar Srivastava; Melissa M Hudson; Leslie L Robison; Kevin R Krull; Tara M Brinkman Journal: Pediatr Blood Cancer Date: 2021-10-21 Impact factor: 3.167
Authors: Emily J Ricketts; Gabrielle E Montalbano; Helen J Burgess; Dana L McMakin; Meredith E Coles; John Piacentini; Christopher S Colwell Journal: J Clin Psychol Date: 2022-02-12
Authors: Jeanne F Duffy; Sabra M Abbott; Helen J Burgess; Stephanie J Crowley; Jonathan S Emens; Lawrence J Epstein; Karen L Gamble; Brant P Hasler; David A Kristo; Roneil G Malkani; Shadab A Rahman; S Justin Thomas; James K Wyatt; Phyllis C Zee; Elizabeth B Klerman Journal: Sleep Date: 2021-05-14 Impact factor: 5.849
Authors: Laura Palagini; Raffaele Manni; Eugenio Aguglia; Mario Amore; Roberto Brugnoli; Stéphanie Bioulac; Patrice Bourgin; Jean-Arthur Micoulaud Franchi; Paolo Girardi; Luigi Grassi; Régis Lopez; Claudio Mencacci; Giuseppe Plazzi; Julia Maruani; Antonino Minervino; Pierre Philip; Sylvie Royant Parola; Isabelle Poirot; Lino Nobili; Giovanni Biggio; Carmen M Schroder; Pierre A Geoffroy Journal: Front Psychiatry Date: 2021-06-10 Impact factor: 4.157